BioMarin Pharmaceutical (BMRN) Projected to Post Quarterly Earnings on Monday

Key Points

• BioMarin Pharmaceutical is expected to release its Q3 2025 earnings on October 27, projecting earnings of $0.89 per share and revenue of $782.4 million.
• The stock currently opens at $54.55, with a market capitalization of $10.47 billion and an average price target from analysts set at $93.26.
• Analysts have mixed ratings for BioMarin, with most giving it a "Moderate Buy" rating, while some targets range significantly, from $85.00 to $119.00.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) is anticipated to issue its Q3 2025 results before the market opens on Monday, October 27th. Analysts expect the company to announce earnings of $0.89 per share and revenue of $782.4240 million for the quarter. Parties may review the information on the company's upcoming Q3 2025 earningreport for the latest details on the call scheduled for Monday, October 27, 2025 at 4:30 PM ET.

BioMarin Pharmaceutical Stock Performance

NASDAQ BMRN opened at $54.55 on Friday. BioMarin Pharmaceutical has a 1 year low of $51.56 and a 1 year high of $73.51. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.56 and a quick ratio of 3.60. The stock has a market capitalization of $10.47 billion, a PE ratio of 16.19, a P/E/G ratio of 0.67 and a beta of 0.33. The company's 50 day simple moving average is $55.35 and its two-hundred day simple moving average is $57.29.

Wall Street Analysts Forecast Growth

BMRN has been the topic of several research reports. Raymond James Financial initiated coverage on shares of BioMarin Pharmaceutical in a research report on Wednesday, September 3rd. They set an "outperform" rating and a $85.00 price objective on the stock. Wall Street Zen cut shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, October 11th. Wolfe Research set a $95.00 price objective on shares of BioMarin Pharmaceutical and gave the company an "outperform" rating in a research report on Tuesday, July 15th. Zacks Research cut shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 13th. Finally, JPMorgan Chase & Co. raised their price objective on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the company an "overweight" rating in a research report on Thursday, October 9th. Thirteen analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical currently has an average rating of "Moderate Buy" and an average price target of $93.26.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in the business. NewEdge Advisors LLC grew its holdings in BioMarin Pharmaceutical by 11.5% in the 1st quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company's stock worth $266,000 after acquiring an additional 388 shares during the last quarter. Empowered Funds LLC grew its holdings in BioMarin Pharmaceutical by 207.4% in the 1st quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company's stock worth $850,000 after acquiring an additional 8,112 shares during the last quarter. Focus Partners Wealth grew its holdings in BioMarin Pharmaceutical by 70.2% in the 1st quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company's stock worth $835,000 after acquiring an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC grew its holdings in BioMarin Pharmaceutical by 33.0% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company's stock worth $244,000 after acquiring an additional 1,102 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in BioMarin Pharmaceutical by 23.5% in the 2nd quarter. Invesco Ltd. now owns 618,835 shares of the biotechnology company's stock worth $34,017,000 after acquiring an additional 117,617 shares during the last quarter. Institutional investors own 98.71% of the company's stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.